Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice

Marie Luise Kromrey, Masatoshi Hori, Satoshi Goshima, Kazuto Kozaka, Tomoko Hyodo, Yuko Nakamura, Akihiro Nishie, Tsutomu Tamada, Tatsuya Shimizu, Akihiko Kanki, Utaroh Motosugi

Research output: Contribution to journalArticle

Abstract

Purpose: To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters. Materials and methods: This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8 years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging. Results: Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1%). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2% vs 7.7%, p < 0.001; subcohort, 17.6% vs 6.3%, p < 0.001) and substantial artifacts in arterial phase (7.2% vs 2.2%, p = 0.001; 7.4% vs 1.7%, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts. Conclusion: Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging. Key Points: • Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan. • Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents. • Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.

Original languageEnglish
JournalEuropean Radiology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Artifacts
Dyspnea
Japan
Odds Ratio
Contrast Media
Gadolinium
Logistic Models
gadolinium ethoxybenzyl DTPA
Hearing

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Gadoxetate disodium-related event during image acquisition : a prospective multi-institutional study for better MR practice. / Kromrey, Marie Luise; Hori, Masatoshi; Goshima, Satoshi; Kozaka, Kazuto; Hyodo, Tomoko; Nakamura, Yuko; Nishie, Akihiro; Tamada, Tsutomu; Shimizu, Tatsuya; Kanki, Akihiko; Motosugi, Utaroh.

In: European Radiology, 01.01.2019.

Research output: Contribution to journalArticle

Kromrey, Marie Luise ; Hori, Masatoshi ; Goshima, Satoshi ; Kozaka, Kazuto ; Hyodo, Tomoko ; Nakamura, Yuko ; Nishie, Akihiro ; Tamada, Tsutomu ; Shimizu, Tatsuya ; Kanki, Akihiko ; Motosugi, Utaroh. / Gadoxetate disodium-related event during image acquisition : a prospective multi-institutional study for better MR practice. In: European Radiology. 2019.
@article{ad1bf2a660a8490cbeb522755aa693ea,
title = "Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice",
abstract = "Purpose: To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters. Materials and methods: This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8 years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging. Results: Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1{\%}). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2{\%} vs 7.7{\%}, p < 0.001; subcohort, 17.6{\%} vs 6.3{\%}, p < 0.001) and substantial artifacts in arterial phase (7.2{\%} vs 2.2{\%}, p = 0.001; 7.4{\%} vs 1.7{\%}, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts. Conclusion: Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging. Key Points: • Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan. • Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents. • Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.",
author = "Kromrey, {Marie Luise} and Masatoshi Hori and Satoshi Goshima and Kazuto Kozaka and Tomoko Hyodo and Yuko Nakamura and Akihiro Nishie and Tsutomu Tamada and Tatsuya Shimizu and Akihiko Kanki and Utaroh Motosugi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00330-019-06358-7",
language = "English",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Gadoxetate disodium-related event during image acquisition

T2 - a prospective multi-institutional study for better MR practice

AU - Kromrey, Marie Luise

AU - Hori, Masatoshi

AU - Goshima, Satoshi

AU - Kozaka, Kazuto

AU - Hyodo, Tomoko

AU - Nakamura, Yuko

AU - Nishie, Akihiro

AU - Tamada, Tsutomu

AU - Shimizu, Tatsuya

AU - Kanki, Akihiko

AU - Motosugi, Utaroh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters. Materials and methods: This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8 years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging. Results: Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1%). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2% vs 7.7%, p < 0.001; subcohort, 17.6% vs 6.3%, p < 0.001) and substantial artifacts in arterial phase (7.2% vs 2.2%, p = 0.001; 7.4% vs 1.7%, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts. Conclusion: Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging. Key Points: • Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan. • Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents. • Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.

AB - Purpose: To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters. Materials and methods: This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8 years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging. Results: Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1%). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2% vs 7.7%, p < 0.001; subcohort, 17.6% vs 6.3%, p < 0.001) and substantial artifacts in arterial phase (7.2% vs 2.2%, p = 0.001; 7.4% vs 1.7%, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts. Conclusion: Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging. Key Points: • Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan. • Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents. • Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.

UR - http://www.scopus.com/inward/record.url?scp=85069679004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069679004&partnerID=8YFLogxK

U2 - 10.1007/s00330-019-06358-7

DO - 10.1007/s00330-019-06358-7

M3 - Article

AN - SCOPUS:85069679004

JO - European Radiology

JF - European Radiology

SN - 0938-7994

ER -